Yahoo · Nov 5, 2026
Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting
Biohaven Ltd. (NYSE: BHVN) (Biohaven) today announced continued progress across its Graves' disease program, including active enrollment in the pivotal Phase 3 trial of BHV-1300 and three scientific presentations at the 2026 American Thyroid Association (ATA) Annual Meeting in Philadelphia, Pennsylvania. Together they describe a program that extends from the molecule in pivotal testing, to the patient experience that defines the need for it, to the underlying autoantibody biology that Biohaven c


